Stockscreener 앱 받기
162.29
2.33%
-3.87
시간 외 거래:
162.29
전일 마감가:
$166.16
열려 있는:
$166.59
하루 거래량:
343.41K
Relative Volume:
1.23
시가총액:
$4.90B
수익:
$290.51M
순이익/손실:
$89.16M
주가수익비율:
54.28
EPS:
2.99
순현금흐름:
$119.18M
1주 성능:
-4.38%
1개월 성능:
-5.26%
6개월 성능:
-6.95%
1년 성능:
+0.74%
1일 변동 폭
$161.71
$167.21
1주일 범위
$161.71
$172.52
52주 변동 폭
$141.72
$219.34
Krystal Biotech Inc Stock (KRYS) Company Profile
명칭
Krystal Biotech Inc
전화
(412) 586-5830
주소
2100 WHARTON STREET, PITTSBURGH, PA
KRYS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
162.29 | 4.90B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-05 | 개시 | Jefferies | Buy |
| 2024-08-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-11-20 | 개시 | Goldman | Buy |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-12 | 개시 | Citigroup | Buy |
| 2023-09-07 | 개시 | Berenberg | Buy |
| 2023-04-18 | 개시 | Stifel | Buy |
| 2023-02-28 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-01-18 | 개시 | BofA Securities | Buy |
| 2021-07-20 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-09-18 | 개시 | B. Riley FBR | Buy |
| 2020-06-04 | 개시 | Evercore ISI | Outperform |
| 2019-09-24 | 개시 | Goldman | Neutral |
| 2019-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-24 | 재확인 | Chardan Capital Markets | Buy |
| 2019-06-24 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-30 | 개시 | Guggenheim | Buy |
| 2018-09-11 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Krystal Biotech Inc 주식(KRYS)의 최신 뉴스
Krystal Biotech Q1 2025 Earnings Preview - MSN
Krystal Biotech Inc (KRYS) Q1 2025 Earnings Report Preview: What to Look For - GuruFocus
Krystal Biotech (KRYS) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Chardan Capital Forecasts Krystal Biotech FY2025 Earnings - Defense World
Where are the Opportunities in (KRYS) - news.stocktradersdaily.com
Commit To Purchase Krystal Biotech At $150, Earn 16.3% Annualized Using Options - Nasdaq
Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Krystal Biotech shares rise as H.C. Wainwright lifts price target By Investing.com - Investing.com Canada
Krystal Biotech (NASDAQ:KRYS) Given New $240.00 Price Target at HC Wainwright - Defense World
Krystal Biotech’s VYJUVEK gets European approval for DEB treatment - Investing.com
Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years - Benzinga
Demystifying Krystal Biotech: Insights From 7 Analyst Reviews - Benzinga
Krystal Biotech (KRYS) Price Target Increased to $240 by H.C. Wa - GuruFocus
Krystal Biotech's Vyjuvek gains European approval for rare skin disease treatmentPittsburgh Business Times - The Business Journals
Krystal Biotech gets EU approval for Vyjuvek (KRYS:NASDAQ) - Seeking Alpha
Krystal Biotech Gets EU Approval to Market Treatment for Dystrophic Epidermolysis Bullosa - marketscreener.com
Krystal Biotech Gains EU Approval for VYJUVEK® - TipRanks
Krystal Biotech’s VYJUVEK gets European approval for DEB treatment By Investing.com - Investing.com Canada
Krystal Biotech (KRYS) Gains EC Approval for VYJUVEK in DEB Trea - GuruFocus
Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa - The Manila Times
Krystal Biotech Receives European Approval for VYJUVEK® to Treat Dystrophic Epidermolysis Bullosa from Birth - Nasdaq
Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa - GlobeNewswire Inc.
Envestnet Asset Management Inc. Has $1.82 Million Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Acquired by LPL Financial LLC - Defense World
Wells Fargo & Company MN Boosts Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Pittsburgh biotech firms benefit in potential pharma tariffs and domestic manufacturing shift - The Business Journals
Krystal Biotech, Inc. to Present Innovative Genetic Medicine Programs at Upcoming Scientific Conferences - Nasdaq
Krystal Biotech to Present at Upcoming Scientific Conferences - The Manila Times
IBD Rating Upgrades: Krystal Biotech Flashes Improved Relative Price Strength - MSN
Bank of Montreal Can Has $521,000 Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Top Growth Companies With High Insider Ownership In April 2025 - simplywall.st
Krystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025 - The Manila Times
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Bought by Alliancebernstein L.P. - Defense World
Wellington Management Group LLP Sells 976 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Recommendation of “Buy” from Analysts - Defense World
Gene Therapy Market Top Players-Krystal Biotech, Inc., - openPR.com
JPMorgan Chase & Co. Buys 23,934 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Krystal Biotech Becomes Oversold (KRYS) - Nasdaq
Krystal Biotech subsidiary Jeune Aesthetics taps Botox veteran as new CEO - The Business Journals
Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Krystal gets positive EU regulatory opinion for Vyjuvek - MSN
Jeune Aesthetics names Marc Forth as new CEO By Investing.com - Investing.com South Africa
Jeune Aesthetics names Marc Forth as new CEO - Investing.com Australia
Jeune Aesthetics Appoints Marc Forth As Chief Executive Officer - MarketScreener
Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer - GlobeNewswire
Aesthetic Medicine Powerhouse: BOTOX Veteran Takes Helm at Jeune Aesthetics - Stock Titan
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025 - Zacks Investment Research
Krystal Biotech Q1 EPS Forecast Reduced by William Blair - Defense World
Krystal Biotech: Some Uncertainty, Some Value (NASDAQ:KRYS) - Seeking Alpha
Norges Bank Purchases New Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
William Blair Raises Earnings Estimates for Krystal Biotech - Defense World
Krystal Biotech Inc (KRYS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):